Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 1999

View Archived Issues

Long-term beneficial effects of orlistat reported in JAMA

Idun obtains rights to technology with application to HIV and other diseases

LeukoSite acquires CytoMed programs in asthma and inflammation

Nitromethyl ketones from Merck KGaA protect against diabetic complications

Melatonergic agents in development at Bristol-Myers Squibb

Ortho-McNeil reports new treatments for BPH

More on AMPA antagonists under study at Pfizer

NOS inhibitors with selectivity for the neuronal isoform synthesized at Schering AG

Preparation and use of dopamine D3 receptor modulators disclosed by SB

DuPont describes new HIV protease inhibitors

Generic form of Ritalin approved by FDA

New treatment option for Gaucher's disease patients in Germany

New market introduction for Organon's anticoagulant

Potential new use for Anticort to be tested in Romania

Zidovudine exposure in infancy not associated with adverse effects later in childhood

SAR studies on biphenylsulfonamides lead to BMS-187308, an orally active endothelin antagonist

Novel pure mu/kappa-opioid receptor antagonist as a lead in the field of drug abuse therapy

XK-469, an analogue of the herbicide Assure, in clinical testing as antitumor agent

New formulation may facilitate clinical development of antagonist G

Pfizer launches Trovan in Canada

PDL issues further licenses under its antibody humanization patents

Pharmacia & Upjohn provides additional funding for Miravant's SnET2

Biovail signs multifaceted agreement with Lundbeck for citalopram

ProCyte and Merck enter distribution agreement

SNAP-5540: a uroselective adrenergic BPH agent

Cantab studies validate novel approach to treating IBD

PARP inhibitors potentiate cytotoxicity of alkylating agents, bleomycin and radiation

Immune Response receives USD 5 million payment from Agouron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...